Company: SMNR
Filing Date: 2025-08-08
Form Type: S-4/A
Source: 0001193125-25-177097
Chunk: 394

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-08
Form: S-4/A
Chunk 394
---
 unless the applicable obligation has a materiality qualifier, in which case, it shall be duly performed in all respects. |

| • |     | All of the representations and warranties of Denali and Merger Sub contained in Article V of the Merger Agreement, disregarding all qualifications and exceptions contained herein relating to materiality or Material Adverse Effect with respect to Denali, regardless of whether it involved a known risk, shall be true and correct at and as of the date of the Merger Agreement and be true and correct as of the Closing Date (other than in each case except for representation and warranties that speak as of a specific date, in which case such representations and warranties need only to be true and correct as of such date), other than as would not in the aggregate reasonably be expected to have a Material Adverse Effect with respect to Denali. |

| • |     | Since the date of the Merger Agreement, no Material Adverse Effect with respect to Denali has occurred that is continuing, regardless of whether it involved a known risk. |

| • |     | Semnur shall have received a certificate signed by an authorized officer of each of Denali and Merger Sub certifying the satisfaction of the conditions described in the preceding three bullet points. |

| • |     | From the date of the Merger Agreement until the Closing, Denali and Merger Sub shall have been in material compliance with the reporting requirements under the Securities Act and the Exchange Act applicable to Denali and Merger Sub, respectively. |

| • |     | Each of Denali and Merger Sub shall have executed and delivered to Semnur each ancillary agreement to be executed in connection with the Business Combination to which it is a party. |

| • |     | The directors designated by Semnur shall have been appointed or elected to the Denali Board, effective at the Effective Time. |

226

| • |     | New Semnur Common Stock and New Semnur Warrants shall remain listed or quoted on the OTC Markets through the Effective Time, and the listing application for the New Semnur Common Stock and the New Semnur Warrants following the Effective Time shall have been approved by the OTC Markets or such other national securities exchange or automated quotation system as agreed to in writing by Denali and Semnur, and as of the Closing Date, Denali shall not have received any written notice from the OTC Markets or such other exchange that it has failed, or would reasonably be expected to fail to